Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
Inovio Pharmaceuticals (INO) Stock Falls -24% Ahead of Key FDA Date

Inovio Pharmaceuticals (INO) Stock Falls -24% Ahead of Key FDA Date

Key Takeaways

  • Inovio Pharmaceuticals (INO) shares fell roughly 24% over the last 30 days, declining from about $1.17 to $0.89, extending a volatile stretch into late October.
  • The slide reflects heightened uncertainty ahead of the U.S. FDA's October 30, 2026 target action date for INO-3107, the company's lead candidate for recurrent respiratory papillomatosis (RRP).
  • A Zacks Research downgrade to Hold on October 12, 2026, and approaching lock-up expirations tied to July's equity offering weighed on near-term sentiment.
  • The broader quarter was choppy: the stock plunged on July dilution, rebounded above $1.40 in early September, then trended steadily lower.
  • A narrower second-quarter net loss and a cash runway into late first-quarter 2027 provide some balance against the binary regulatory risk.
  • Get more detail on this ticker's Price Targets, Earnings, and Forecast.
  • Explore how top-performing Trending AI Robots are positioning across the market.

Inovio Pharmaceuticals (INO) Company Overview and Market Position

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on DNA medicines designed to treat and protect against HPV-related diseases, cancer, and infectious diseases. Its platform uses proprietary investigational CELLECTRA delivery devices to administer DNA plasmids without chemical adjuvants, lipid nanoparticles, or viral vectors.

The company's lead candidate, INO-3107, is under FDA review for the treatment of recurrent respiratory papillomatosis (RRP), a rare, chronic disease caused by HPV types 6 and 11. Inovio's broader pipeline includes INO-3112 for HPV-related oropharyngeal cancer, VGX-3100 for cervical and anal high-grade lesions, and INO-5401 for glioblastoma. Investors follow the stock primarily for its binary regulatory catalyst and the potential first commercial launch from its DNA medicines platform. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Inovio Pharmaceuticals (INO) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, INO declined from a closing price of $1.17 on September 28, 2026, to $0.89 on October 27, 2026, a drop of approximately 23.9%. The move was not linear; the stock posted sharp single-session declines in mid-October, including a slide from $1.01 to $0.80 on October 21, before stabilizing near the $0.85–$0.90 range.

The last quarter tells a broader story of extreme volatility. In late July, the stock traded around $1.03, then collapsed roughly 37% in a single session on July 30 following a public equity offering that raised about $18.3 million in net proceeds. Shares subsequently recovered on second-quarter results and analyst upgrades, climbing above $1.40 by early September, before a sustained decline brought the stock back toward $0.89. Net of the swing, INO is down roughly 14% over the trailing three months.

What Drove INO Stock Price in the Last 30 Days

The dominant driver of the recent decline is the approaching PDUFA target action date of October 30, 2026 for the INO-3107 Biologics License Application. With a binary regulatory outcome looming, risk positioning and profit-taking contributed to elevated volatility.

Several verified developments added pressure. On October 12, 2026, Zacks Research downgraded the stock to Hold. Separately, lock-up agreements tied to the July 2026 equity offering were scheduled to expire on October 28, 2026, creating a near-term overhang tied to potential share sales by insiders and holders of restricted units, warrants, and options. Notably, Piper Sandler reiterated a Buy rating with a $4.00 price target on October 21, underscoring the divided sentiment around the stock as the decision date neared. From what I see, this combination of regulatory uncertainty, the analyst downgrade, and dilution-related concerns outweighed the supportive elements and drove the 30-day decline.

What Drove INO Stock Performance Over the Last Quarter

The quarter was defined first by financing and then by sentiment swings around the regulatory timeline. The July 30 offering sharply diluted existing shareholders, sending the stock to a multi-month low. Inovio reported a second-quarter GAAP net loss of $6.01 million, a meaningful improvement from $23.52 million a year earlier, and guided that its cash position would fund operations into late first-quarter 2027, through a potential launch of INO-3107. An analyst upgrade and the company's progress through late-cycle review and pre-licensure inspections helped fuel a rebound toward $1.45 in early September.

Since that peak, the stock has given back those gains as the market de-risked ahead of the FDA decision, reflecting the event-driven nature of the investment case rather than any change in the underlying regulatory timeline.

INO Stock Forecast Drivers: What Investors Should Watch Next

The single most important catalyst is the FDA's decision on INO-3107, with a target action date of October 30, 2026. The outcome will directly shape the company's commercial trajectory, cash needs, and investor sentiment. Beyond the decision, investors should monitor any feedback on the confirmatory trial design, label negotiations, and the pace of a potential commercial launch supported by contract sales partner Syneos Health.

Additional factors include progress on VGX-3100 following positive Phase III data in China reported by partner ApolloBio, the advancement of the DPROT technology platform, and the company's cash position and potential future financing. Competitive dynamics in RRP, particularly relative to recently approved treatments, and broader small-cap biotech risk appetite will also influence the stock. These are forward-looking considerations, not predictions, and all investments carry risk. I'm watching this closely as the decision date approaches.

Exploring AI Tools for Biotech Stock Analysis

In my research process, I often review Tickeron’s Trending AI Robots to see how automated strategies are positioning around volatile names like this one. The page highlights top-performing bots across different timeframes and approaches, which can add useful context on momentum when paired with fundamental work on event-driven biotech stocks. It is one part of a broader toolkit that helps frame market signals without replacing core analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: INO

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


INO's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for INO turned positive on November 02, 2026. Looking at past instances where INO's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

INO moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for INO crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.

Following a +6.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 185 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The 10-day RSI Indicator for INO moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 20 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 47 cases where INO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INO as a result. In 62 of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

INO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for INO entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. INO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (28.741) is normal, around the industry mean (3.586). P/E Ratio (-1.180) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of synthetic vaccines and immune therapies for cancers and infectious diseases

Industry Biotechnology

Industry
Medical Specialties
Address
660 West Germantown Pike
Phone
+1 267 440-4200
Employees
112
Web
https://www.inovio.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
Inovio Pharmaceuticals (INO) Stock Falls -24% Ahead of Key FDA Date